Author/Authors :
firouzi, ata iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , kazem moussavi, ali iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , mohebbi, ahmad iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , alemzadeh-ansari, mohammad javad iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , kiani, reza iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , sanati, hamid reza iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , mohebbi, bahram iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , shakerian, farshad iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , zahedmehr, ali iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , ansari-ramandi, mohammad mostafa iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , heris, saeed oni iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , ghaleshi, bahar iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran , ghorbani, fatemeh iran university of medical sciences - rajaie cardiovascular medical and research center, Tehran, Iran
Abstract :
Introduction: There is some controversy over the efficacy of statins for the prevention of contrast induced nephropathy (CIN). There have also been reports on varying efficacies of different statins. Hence, in this study the efficacy of atorvastatin and rosuvastatin for the prevention of CIN was assessed. Methods: This single-blind randomized clinical trial was performed on 495 random patients with myocardial infarction with ST-segment elevation undergoing primary percutaneous coronary intervention (PCI) in a training referral hospital in 2015. Patients were randomly assigned to receive either atorvastatin 80 mg at admission and daily or rosuvastatin 40 mg at admission and daily. CIN was defined based on serum creatinine elevation after 48 hours from the PCI. Results: The incidence of CIN was observed in 63 patients (21.4%) After 48 hours from primary PCI. Of those, 17% (n = 50) were grade 1 CIN, while 4.4% (n = 13) were grade 2 CIN. There was no significant difference between rosuvastatin group compared with atorvastatin group, regarding the CIN grading (P = 0.14). Conclusion: Our results indicate that atorvastatin and rosuvastatin have similar efficacy for the prevention of CIN.
